الصفحة الرئيسية>>Lipids>> P450>>19S(20R)-EpDPA

19S(20R)-EpDPA (Synonyms: 19S,20R-EDP, 19S,20R-EpDPE, 19S,20R-epoxy DPA, 19S,20R-epoxy Docosapentaenoic Acid)

رقم الكتالوجGC46476

A neuropeptide with diverse biological activities

Products are for research use only. Not for human use. We do not sell to patients.

19S(20R)-EpDPA التركيب الكيميائي

Cas No.: 2460392-58-7

الحجم السعر المخزون الكميّة
25 μg
57٫00
متوفر
50 μg
108٫00
متوفر
100 μg
204٫00
متوفر
500 μg
904٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com


مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

19S(20R)-EpDPA is an oxylipin and a metabolite of docosahexaenoic acid .1,2 It is formed from DHA by various cytochrome P450 (CYP) isoforms in a stereoselective manner.2 Unlike 19R(20S)-EpDPA , 19S(20R)-EpDPA does not prevent calcium-induced increases in the spontaneous beating of isolated neonatal rat cardiomyocytes (NRCMs).3

1.Cinelli, M.A., Yang, J., Scharmen, A., et al.Enzymatic synthesis and chemical inversion provide both enantiomers of bioactive epoxydocosapentaenoic acidsJ. Lipid Res.59(11)2237-2252(2018) 2.Lucas, D., Goulitquer, S., Marienhagen, J., et al.Stereoselective epoxidation of the last double bond of polyunsaturated fatty acids by human cytochromes P450J. Lipid Res.51(5)1125-1133(2010) 3.Burke, J.E., and Dennis, E.A.Phospholipase A2 structure/function, mechanism, and signalingJ. Lipid Res.50(Suppl)S237-S242(2009)

مراجعات

Review for 19S(20R)-EpDPA

Average Rating: 5 ★★★★★ (Based on Reviews and 19 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for 19S(20R)-EpDPA

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.